

Rui-Hua Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2285082/publications.pdf>

Version: 2024-02-01

370
papers

23,667
citations

10979

71
h-index

11928

134
g-index

384
all docs

384
docs citations

384
times ranked

27262
citing authors

#	ARTICLE	IF	CITATIONS
1	Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. <i>Cancer Communications</i> , 2019, 39, 1-12.	3.7	1,177
2	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1448-1454.	0.8	756
3	Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. <i>Nature Materials</i> , 2017, 16, 1155-1161.	13.3	641
4	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 619-629.	5.1	574
5	Circular RNA: metabolism, functions and interactions with proteins. <i>Molecular Cancer</i> , 2020, 19, 172.	7.9	526
6	Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i> -Amplified Advanced Gastric Cancer in Asian Populations: TyTANâ€”A Randomized, Phase III Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2039-2049.	0.8	524
7	METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma. <i>Molecular Cancer</i> , 2019, 18, 112.	7.9	515
8	Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. <i>Cancer Research</i> , 2005, 65, 613-21.	0.4	506
9	N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. <i>Nature Communications</i> , 2019, 10, 4695.	5.8	418
10	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	3.7	418
11	DNA methylation markers for diagnosis and prognosis of common cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7414-7419.	3.3	387
12	Cancer incidence, mortality, and burden in China: a timeâ€”trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. <i>Cancer Communications</i> , 2021, 41, 1037-1048.	3.7	358
13	Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. <i>Journal of Cell Biology</i> , 2006, 175, 913-923.	2.3	345
14	Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. <i>Annals of Oncology</i> , 2019, 30, 1479-1486.	0.6	336
15	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	3.7	323
16	LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. <i>Molecular Cancer</i> , 2019, 18, 174.	7.9	315
17	Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 916.	3.8	310
18	Evaluation of <i>POLE</i> and <i>POLD1</i> Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. <i>JAMA Oncology</i> , 2019, 5, 1504.	3.4	287

#	ARTICLE	IF	CITATIONS
19	LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. <i>Cancer Communications</i> , 2021, 41, 109-120.	3.7	271
20	Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. <i>Theranostics</i> , 2017, 7, 4836-4849.	4.6	265
21	Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. <i>Lancet Oncology</i> , The, 2019, 20, 1645-1654.	5.1	263
22	Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	260
23	Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. <i>Nature Communications</i> , 2019, 10, 1858.	5.8	242
24	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1637-1651.	5.1	233
25	Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 142.	3.5	227
26	CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. <i>Oncogene</i> , 2018, 37, 6025-6040.	2.6	211
27	Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). <i>Gastric Cancer</i> , 2015, 18, 168-176.	2.7	209
28	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	3.8	202
29	Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. <i>Biomarkers</i> , 2010, 15, 516-522.	0.9	199
30	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1536-1543.	15.2	197
31	NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 231.	7.1	194
32	Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. <i>Medical Oncology</i> , 2012, 29, 3092-3100.	1.2	187
33	Pattern of distant metastases in colorectal cancer: a SEER based study. <i>Oncotarget</i> , 2015, 6, 38658-38666.	0.8	182
34	Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. <i>Cancer Cell</i> , 2022, 40, 277-288.e3.	7.7	177
35	Long noncoding RNA XIST expedites metastasis and modulates epithelial-mesenchymal transition in colorectal cancer. <i>Cell Death and Disease</i> , 2017, 8, e3011-e3011.	2.7	170
36	Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis. <i>Theranostics</i> , 2019, 9, 1965-1979.	4.6	168

#	ARTICLE	IF	CITATIONS
37	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 350-358.	0.8	160
38	Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. <i>Breast Cancer Research</i> , 2014, 16, 434.	2.2	157
39	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). <i>Journal of Clinical Oncology</i> , 2021, 39, 704-712.	0.8	156
40	Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. <i>Journal of Translational Medicine</i> , 2013, 11, 58.	1.8	142
41	Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. <i>Nature Genetics</i> , 2019, 51, 1131-1136.	9.4	133
42	Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor. <i>Clinical Cancer Research</i> , 2012, 18, 4059-4069.	3.2	129
43	Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer. <i>IScience</i> , 2020, 23, 101302.	1.9	128
44	Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. <i>Trends in Molecular Medicine</i> , 2021, 27, 482-500.	3.5	128
45	Xc ⁻ inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. <i>Cancer Letters</i> , 2015, 368, 88-96.	3.2	127
46	A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. <i>BMC Cancer</i> , 2015, 15, 350.	1.1	126
47	Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2019, 111, 584-596.	3.0	125
48	Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. <i>Nature Communications</i> , 2020, 11, 1507.	5.8	121
49	Overexpression of the Circadian Clock Gene <i>Bmal1</i> Increases Sensitivity to Oxaliplatin in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1042-1052.	3.2	120
50	High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. <i>Cancer</i> , 2007, 109, 1360-1364.	2.0	119
51	Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. <i>Gut</i> , 2019, 68, 1152-1161.	6.1	118
52	Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. <i>Hepatology</i> , 2014, 60, 598-609.	3.6	117
53	CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 142.	1.8	115
54	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. <i>Theranostics</i> , 2018, 8, 5213-5230.	4.6	115

#	ARTICLE	IF	CITATIONS
55	APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. <i>Journal of Clinical Investigation</i> , 2019, 129, 727-743.	3.9	114
56	CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17. <i>Molecular Cancer</i> , 2020, 19, 60.	7.9	110
57	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671.	5.1	107
58	Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. <i>Chinese Journal of Cancer</i> , 2011, 30, 682-689.	4.9	103
59	ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. <i>International Journal of Cancer</i> , 2012, 131, 461-468.	2.3	102
60	Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. <i>Tumor Biology</i> , 2012, 33, 749-756.	0.8	101
61	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2558-2567.	0.8	98
62	Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. <i>Carcinogenesis</i> , 2013, 34, 803-811.	1.3	96
63	OSW-1: a Natural Compound With Potent Anticancer Activity and a Novel Mechanism of Action. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1781-1785.	3.0	91
64	Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 234-244.	2.7	90
65	A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10168.	3.3	90
66	Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 80.	6.9	90
67	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
68	Structure of Schlafen13 reveals a new class of tRNA/rRNA-targeting RNase engaged in translational control. <i>Nature Communications</i> , 2018, 9, 1165.	5.8	87
69	ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis. <i>Cancer Research</i> , 2018, 78, 1972-1985.	0.4	86
70	YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1643-1648.	3.3	85
71	Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 54.	7.1	84
72	MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e155.	1.7	80

#	ARTICLE	IF	CITATIONS
73	Effective Elimination of Cancer Stem Cells By a Novel Drug Combination Strategy. <i>Stem Cells</i> , 2013, 31, 23-34.	1.4	79
74	Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER-based study. <i>Cancer Medicine</i> , 2018, 7, 3662-3672.	1.3	78
75	Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2017, 8, 14437.	5.8	77
76	FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis. <i>Oncogene</i> , 2021, 40, 5168-5181.	2.6	77
77	Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. <i>Cancer Communications</i> , 2021, 41, 1173-1182.	3.7	77
78	METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 115.	1.3	76
79	Redox Regulation of Stem-like Cells Through the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications. <i>Theranostics</i> , 2016, 6, 1160-1175.	4.6	75
80	Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-Bromopyruvate Propyl Ester. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 117-125.	1.0	73
81	Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. <i>Genome Medicine</i> , 2022, 14, 45.	3.6	73
82	KIF2C: a novel link between Wnt/ β -catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma. <i>Protein and Cell</i> , 2021, 12, 788-809.	4.8	71
83	Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. <i>Cancer Communications</i> , 2021, 41, 1100-1115.	3.7	71
84	Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells. <i>Theranostics</i> , 2020, 10, 498-515.	4.6	68
85	A Coiled-Coil Domain Containing 50 Splice Variant Is Modulated by Serine/Arginine-Rich Splicing Factor 3 and Promotes Hepatocellular Carcinoma in Mice by the Ras Signaling Pathway. <i>Hepatology</i> , 2019, 69, 179-195.	3.6	67
86	CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma. <i>Cancer Research</i> , 2016, 76, 7277-7289.	0.4	66
87	Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. , 2019, 7, 264.		66
88	Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11084-91.	0.5	66
89	Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. <i>Cancer Letters</i> , 2018, 412, 243-255.	3.2	65
90	The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. <i>Molecular Cancer</i> , 2020, 19, 154.	7.9	64

#	ARTICLE	IF	CITATIONS
91	microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. <i>Oncotarget</i> , 2015, 6, 10868-10879.	0.8	64
92	Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 16.	1.8	63
93	Right- and left-sided colorectal cancers respond differently to cetuximab. <i>Chinese Journal of Cancer</i> , 2015, 34, 384-93.	4.9	63
94	Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. <i>Cancer Letters</i> , 2020, 473, 74-89.	3.2	63
95	Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. <i>World Journal of Gastroenterology</i> , 2011, 17, 4779.	1.4	62
96	The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 435-444.	2.0	61
97	The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. <i>Molecular Cancer</i> , 2021, 20, 166.	7.9	60
98	HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation. <i>International Journal of Cancer</i> , 2014, 134, 2468-2477.	2.3	59
99	Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. <i>Supportive Care in Cancer</i> , 2015, 23, 1933-1939.	1.0	58
100	Comparison of 6th and 7th AJCC TNM Staging Classification for Carcinoma of the Stomach in China. <i>Annals of Surgical Oncology</i> , 2011, 18, 1869-1876.	0.7	57
101	The Tumor-Log Odds of Positive Lymph Nodes-Metastasis Staging System, a Promising New Staging System for Gastric Cancer after D2 Resection in China. <i>PLoS ONE</i> , 2012, 7, e31736.	1.1	57
102	Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2008, 8, 115.	1.1	56
103	Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies. <i>Theranostics</i> , 2019, 9, 1115-1124.	4.6	56
104	Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. <i>BMC Cancer</i> , 2014, 14, 823.	1.1	55
105	Impact of pretreatment hematologic profile on survival of colorectal cancer patients. <i>Tumor Biology</i> , 2010, 31, 255-260.	0.8	53
106	DNA polymerase β protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. <i>Journal of Translational Medicine</i> , 2010, 8, 126.	1.8	53
107	Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer. <i>Nanoscale</i> , 2016, 8, 11543-11558.	2.8	53
108	Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor κ B activation. <i>Journal of Pineal Research</i> , 2016, 60, 27-38.	3.4	53

#	ARTICLE	IF	CITATIONS
109	Inhibition of the NF- κ B pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. <i>Cancer Letters</i> , 2016, 380, 87-97.	3.2	53
110	L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. <i>Journal of Hematology and Oncology</i> , 2013, 6, 43.	6.9	52
111	Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2413-2424.	1.2	52
112	Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer. <i>Molecular Therapy</i> , 2021, 29, 587-596.	3.7	52
113	Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. <i>Cancer Letters</i> , 2016, 379, 1-11.	3.2	51
114	VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients. <i>Chest</i> , 2019, 155, 114-122.	0.4	51
115	Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1975-1981.	0.7	50
116	<i>MET</i> amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. <i>Cancer</i> , 2014, 120, 675-682.	2.0	50
117	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 22.	6.9	50
118	Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. <i>Tumor Biology</i> , 2010, 31, 633-641.	0.8	49
119	Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. <i>Cell Death and Disease</i> , 2016, 7, e2432-e2432.	2.7	49
120	Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer. <i>Journal of Cancer</i> , 2017, 8, 950-958.	1.2	49
121	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. <i>Cell Reports Medicine</i> , 2021, 2, 100383.	3.3	49
122	MYC-Activated LncRNA <i>MX1-AS1</i> Promotes the Progression of Colorectal Cancer by Stabilizing YB1. <i>Cancer Research</i> , 2021, 81, 2636-2650.	0.4	48
123	Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. <i>Oncotarget</i> , 2014, 5, 10778-10790.	0.8	48
124	Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). <i>Journal of Translational Medicine</i> , 2012, 10, 21.	1.8	47
125	β -Phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. <i>Biochemical Pharmacology</i> , 2013, 85, 486-496.	2.0	47
126	Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big data intelligence platform-based analysis from an endemic area. <i>Cancer</i> , 2017, 123, 3540-3549.	2.0	47

#	ARTICLE	IF	CITATIONS
127	Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation. <i>Theranostics</i> , 2018, 8, 1312-1326.	4.6	46
128	The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. <i>Annals of Hematology</i> , 2008, 87, 481-485.	0.8	44
129	Expressions of hypoxia-inducible factor-1 α and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features. <i>Tumor Biology</i> , 2011, 32, 159-166.	0.8	44
130	qPhos: a database of protein phosphorylation dynamics in humans. <i>Nucleic Acids Research</i> , 2019, 47, D451-D458.	6.5	44
131	3-D RoI-Aware U-Net for Accurate and Efficient Colorectal Tumor Segmentation. <i>IEEE Transactions on Cybernetics</i> , 2021, 51, 5397-5408.	6.2	44
132	Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 3858.	1.4	44
133	Prognostic relevance of BRD7 expression in colorectal carcinoma. <i>European Journal of Clinical Investigation</i> , 2013, 43, 131-140.	1.7	41
134	Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. <i>International Journal of Cancer</i> , 2020, 146, 272-280.	2.3	41
135	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. <i>Oncotarget</i> , 2014, 5, 4529-4542.	0.8	41
136	Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. <i>Stem Cell Research and Therapy</i> , 2015, 6, 198.	2.4	40
137	Ratio of Metastatic To Resected Lymph Nodes Enhances To Predict Survival In Patients With Stage III Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 1568-1574.	0.7	39
138	Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. <i>Oncotarget</i> , 2016, 7, 50656-50665.	0.8	39
139	Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: Results from the surveillance epidemiology and end results (SEER) database. <i>Oncotarget</i> , 2015, 6, 33935-33943.	0.8	39
140	Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 619-30.	0.5	39
141	Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer. <i>Chemotherapy</i> , 2010, 56, 94-100.	0.8	38
142	Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. <i>International Journal of Cancer</i> , 2017, 141, 152-159.	2.3	38
143	Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 196.	3.5	38
144	Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 18404.	1.4	38

#	ARTICLE	IF	CITATIONS
145	Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/ β -Catenin Signaling. PLoS ONE, 2013, 8, e56959.	1.1	37
146	Designing gene panels for tumor mutational burden estimation: the need to shift from "correlation"™ to "accuracy"™. , 2019, 7, 206.		37
147	Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism. Cancers, 2019, 11, 931.	1.7	37
148	Multiparametric MRI and Whole Slide Image-Based Pretreatment Prediction of Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Multicenter Radiopathomic Study. Annals of Surgical Oncology, 2020, 27, 4296-4306.	0.7	37
149	Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Theranostics, 2021, 11, 7018-7028.	4.6	37
150	PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. Oncoimmunology, 2020, 9, 1711650.	2.1	37
151	Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. Journal of Translational Medicine, 2013, 11, 277.	1.8	35
152	Editorial announcement regarding title change of <i>Chinese Journal of Cancer</i> to <i>Cancer Communications</i>. Cancer Communications, 2018, 38, 1-1.	3.7	35
153	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. Cancer Biology and Medicine, 2020, 17, 896-909.	1.4	35
154	The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. Journal of Translational Medicine, 2013, 11, 249.	1.8	34
155	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. International Journal of Cancer, 2019, 144, 2161-2168.	2.3	34
156	Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. Tumor Biology, 2011, 32, 509-514.	0.8	33
157	HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World Journal of Gastroenterology, 2011, 17, 804.	1.4	33
158	Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1065-1072.	1.1	33
159	The progress of targeted therapy in advanced gastric cancer. Biomarker Research, 2013, 1, 32.	2.8	33
160	The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumor Biology, 2016, 37, 1879-1887.	0.8	33
161	Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the <sc>UK Biobank</sc>. International Journal of Cancer, 2021, 148, 1867-1878.	2.3	33
162	Impact of marital status on survival of gastric adenocarcinoma patients: Results from the Surveillance Epidemiology and End Results (SEER) Database. Scientific Reports, 2016, 6, 21098.	1.6	32

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1015-1024.	3.7	32
164	Are Risk Factors Associated with Outcomes in Pancreatic Cancer?. <i>PLoS ONE</i> , 2012, 7, e41984.	1.1	31
165	Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. <i>BMC Cancer</i> , 2019, 19, 460.	1.1	30
166	VDR α SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 183.	7.1	30
167	A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. <i>Cancer Communications</i> , 2020, 40, 345-354.	3.7	30
168	A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China. <i>Medical Oncology</i> , 2011, 28, 268-273.	1.2	29
169	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. <i>Chinese Journal of Cancer</i> , 2017, 36, 97.	4.9	28
170	Low preoperative albumin-globulin score predicts favorable survival in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 30550-30560.	0.8	28
171	Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. <i>Oral Oncology</i> , 2012, 48, 1146-1151.	0.8	27
172	The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e83921.	1.1	27
173	The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. <i>Cancer Communications</i> , 2019, 39, 26.	3.7	26
174	EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 382-390.	3.2	25
175	High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. <i>European Journal of Cancer Prevention</i> , 2012, 21, 261-267.	0.6	25
176	Validation and ranking of seven staging systems of hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 705-714.	0.8	25
177	Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. <i>BMC Cancer</i> , 2020, 20, 131.	1.1	25
178	A Feedback Circuitry between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 675-688.	0.4	25
179	ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4000-4000.	0.8	25
180	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 695-710.	2.3	25

#	ARTICLE	IF	CITATIONS
181	A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer. <i>Chemotherapy</i> , 2008, 54, 228-235.	0.8	24
182	Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy. <i>Medicine (United States)</i> , 2015, 94, e1793.	0.4	24
183	Comparison of survival between right-sided and left-sided colon cancer in different situations. <i>Cancer Medicine</i> , 2018, 7, 1141-1150.	1.3	24
184	Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis. <i>Stem Cells</i> , 2018, 36, 180-191.	1.4	24
185	Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. <i>Tumor Biology</i> , 2014, 35, 4369-4375.	0.8	23
186	The genomic landscape of small cell carcinoma of the esophagus. <i>Cell Research</i> , 2018, 28, 771-774.	5.7	23
187	PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 475.	1.8	23
188	Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China. <i>Journal of Medical Economics</i> , 2020, 23, 456-463.	1.0	23
189	S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e82798.	1.1	23
190	Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. <i>Oncotarget</i> , 2016, 7, 57290-57300.	0.8	23
191	The clinicopathologic relevance and prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapy. <i>Oncotarget</i> , 2016, 7, 75094-75103.	0.8	23
192	S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. <i>Oncotarget</i> , 2015, 6, 35107-35115.	0.8	23
193	Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 65.	4.9	22
194	The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy. <i>Journal of Cancer</i> , 2018, 9, 3467-3478.	1.2	22
195	Correlation between immune signature and high-density lipoprotein cholesterol level in stage II/III colorectal cancer. <i>Cancer Medicine</i> , 2019, 8, 1209-1217.	1.3	22
196	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
197	Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy. <i>PLoS ONE</i> , 2013, 8, e53149.	1.1	22
198	Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. <i>Oncotarget</i> , 2016, 7, 6335-6344.	0.8	22

#	ARTICLE	IF	CITATIONS
199	Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. <i>Journal of Translational Medicine</i> , 2010, 8, 107.	1.8	21
200	A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2015, 5, 17717.	1.6	21
201	Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2623-2634.	2.0	21
202	The lncRNA XIST/miRâ€125bâ€2â€3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer. <i>Cancer Medicine</i> , 2021, 10, 2423-2441.	1.3	21
203	JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA2-LBA2.	0.8	21
204	Comprehensive profiling of 1015 patientsâ€™ exomes reveals genomic-clinical associations in colorectal cancer. <i>Nature Communications</i> , 2022, 13, 2342.	5.8	21
205	Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer. <i>Journal of Cancer</i> , 2017, 8, 3531-3537.	1.2	20
206	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018, 14, 2031-2044.	1.1	20
207	Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma. <i>Journal of Translational Medicine</i> , 2012, 10, 181.	1.8	19
208	Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68974.	1.1	19
209	Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer. <i>BMC Cancer</i> , 2014, 14, 650.	1.1	19
210	SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. <i>Gene</i> , 2018, 640, 43-50.	1.0	19
211	Phase III clinical trial of Sâ€1 plus nanoparticle albuminâ€bound paclitaxel in untreated patients with metastatic gastric cancer. <i>Cancer Science</i> , 2018, 109, 3575-3582.	1.7	19
212	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2â€positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	19
213	The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4010-4010.	0.8	19
214	ARRYâ€334543 Reverses Multidrug Resistance by Antagonizing the Activity of ATPâ€Binding Cassette Subfamily G Member 2. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 1381-1391.	1.2	18
215	Effect of Raf kinase inhibitor protein expression on malignant biological behavior and progression of colorectal cancer. <i>Oncology Reports</i> , 2015, 34, 2106-2114.	1.2	18
216	The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy. <i>Tumor Biology</i> , 2015, 36, 8213-8219.	0.8	18

#	ARTICLE	IF	CITATIONS
217	Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 151-159.	1.3	18
218	Expert opinions on immunotherapy for patients with colorectal cancer. <i>Cancer Communications</i> , 2020, 40, 467-472.	3.7	18
219	Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 805-811.	2.3	18
220	Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4011-LBA4011.	0.8	18
221	Phase 2 Study of Capecitabine and Irinotecan Combination Chemotherapy (Modified XELIRI Regimen) in Patients With Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 555-560.	0.6	17
222	The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?. <i>Journal of Cancer</i> , 2017, 8, 1179-1186.	1.2	17
223	Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 391-398.	1.4	17
224	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198899.	1.4	17
225	Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. <i>Gut</i> , 2022, 71, 1340-1349.	6.1	17
226	Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer. <i>PLoS ONE</i> , 2014, 9, e89965.	1.1	17
227	Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer. <i>Clinical Epigenetics</i> , 2021, 13, 232.	1.8	17
228	Pathological Assessment of the AJCC Tumor Regression Grading System After Preoperative Chemoradiotherapy for Chinese Locally Advanced Rectal Cancer. <i>Medicine (United States)</i> , 2016, 95, e2272.	0.4	16
229	A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients. <i>Cell Death Discovery</i> , 2018, 4, 116.	2.0	16
230	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. <i>Journal of Cancer</i> , 2018, 9, 4325-4333.	1.2	16
231	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	1.4	16
232	AMPK β 1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. <i>Oncogene</i> , 2020, 39, 637-650.	2.6	16
233	Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093743.	1.4	16
234	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	1.4	16

#	ARTICLE	IF	CITATIONS
235	Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. <i>Oncotarget</i> , 2016, 7, 28356-28368.	0.8	16
236	Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases. <i>BMC Cancer</i> , 2014, 14, 222.	1.1	15
237	Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. <i>Ecological Management and Restoration</i> , 2016, 30, 1-8.	0.2	15
238	<p>Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3721-3739.	0.9	15
239	Evaluation of Safety of Treatment With Anti“Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2022, 8, 1042.	3.4	15
240	Prognostic analysis in node-negative gastric cancer patients in China. <i>Tumor Biology</i> , 2011, 32, 489-492.	0.8	14
241	Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. <i>Tumor Biology</i> , 2011, 32, 697-705.	0.8	14
242	Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. <i>Medicine (United States)</i> , 2016, 95, e4531.	0.4	14
243	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. <i>Chinese Journal of Cancer</i> , 2016, 35, 13.	4.9	14
244	Evaluation of a wearable wireless device with artificial intelligence, iThermonitor WT705, for continuous temperature monitoring for patients in surgical wards: a prospective comparative study. <i>BMJ Open</i> , 2020, 10, e039474.	0.8	14
245	Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). <i>Oncologist</i> , 2021, 26, e954-e962.	1.9	14
246	The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 712760.	1.3	14
247	LncRNA TMPO-AS1 promotes esophageal squamous cell carcinoma progression by forming biomolecular condensates with FUS and p300 to regulate TMPO transcription. <i>Experimental and Molecular Medicine</i> , 2022, 54, 834-847.	3.2	14
248	Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis. <i>Oncogene</i> , 2022, 41, 3912-3924.	2.6	14
249	Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. <i>Biomarkers</i> , 2010, 15, 243-248.	0.9	13
250	Defeating cancer: the 150 most important questions in cancer research and clinical oncology. <i>Chinese Journal of Cancer</i> , 2016, 35, 104.	4.9	13
251	Genome-wide analysis of Epstein-Barr virus identifies variants and genes associated with gastric carcinoma and population structure. <i>Tumor Biology</i> , 2017, 39, 101042831771419.	0.8	13
252	Proposal for a New TNM Stage based on the 7th and 8th American Joint Committee on Cancer pTNM Staging Classification for Gastric Cancer. <i>Journal of Cancer</i> , 2018, 9, 3570-3576.	1.2	13

#	ARTICLE	IF	CITATIONS
253	Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. <i>Clinical and Translational Medicine</i> , 2020, 10, 353-362.	1.7	13
254	Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms. <i>Oncotarget</i> , 2016, 7, 39945-39956.	0.8	13
255	Association between compliance with enhanced recovery after surgery (ERAS) protocols and postoperative outcome in patients with primary liver cancer undergoing hepatic resection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3047-3059.	1.2	13
256	Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. <i>International Journal of Biological Markers</i> , 2009, 24, 258-264.	0.7	12
257	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
258	Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. <i>Medical Oncology</i> , 2016, 33, 71.	1.2	12
259	Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients. <i>Journal of Cancer</i> , 2018, 9, 512-520.	1.2	12
260	Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. <i>Journal of Cancer</i> , 2020, 11, 1063-1074.	1.2	12
261	Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study. <i>Investigational New Drugs</i> , 2021, 39, 836-845.	1.2	12
262	Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. <i>International Journal of Biological Markers</i> , 2009, 24, 258-264.	0.7	12
263	<i>Annona squamosa</i> Linn: cytotoxic activity found in leaf extract against human tumor cell lines. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2014, 27, 1559-63.	0.2	12
264	MGMT in colorectal cancer: a promising component of personalized treatment. <i>Tumor Biology</i> , 2016, 37, 11443-11456.	0.8	11
265	Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. <i>Journal of Cancer</i> , 2017, 8, 3498-3505.	1.2	11
266	Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study. <i>BMC Cancer</i> , 2017, 17, 885.	1.1	11
267	Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases. <i>Chinese Journal of Cancer</i> , 2017, 36, 78.	4.9	11
268	γRII and III polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5065-5076.	1.0	11
269	Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy. <i>Journal of Cancer</i> , 2018, 9, 660-666.	1.2	11
270	Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2020-107230.	1.5	11

#	ARTICLE	IF	CITATIONS
271	Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. <i>Journal of Cancer</i> , 2016, 7, 694-701.	1.2	10
272	The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching. <i>Journal of Cancer</i> , 2019, 10, 602-610.	1.2	10
273	Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. <i>Gastroenterology Report</i> , 2021, 9, 560-570.	0.6	10
274	Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. , 2021, 9, e002114.		10
275	Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 403-407.	0.7	10
276	Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e63458.	1.1	9
277	Applying chemical bile duct embolization to achieve chemical hepatectomy in hepatolithiasis: a further experimental study. <i>Journal of Surgical Research</i> , 2014, 187, 113-121.	0.8	9
278	Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. <i>Medical Oncology</i> , 2015, 32, 469.	1.2	9
279	Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing transarterial chemoembolization therapy. <i>Oncology Letters</i> , 2017, 15, 855-862.	0.8	9
280	Hypermethylation of APC2 Is a Predictive Epigenetic Biomarker for Chinese Colorectal Cancer. <i>Disease Markers</i> , 2018, 2018, 1-7.	0.6	9
281	Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor β overexpression in human pancreatic carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 175-184.	1.4	8
282	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	2.8	8
283	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1307-1316.	1.4	8
284	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. <i>Advances in Therapy</i> , 2020, 37, 4585-4598.	1.3	8
285	A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16059-e16059.	0.8	8
286	Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1161-e1170.	1.9	8
287	Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 661-674.	2.0	8
288	The extramural metastasis might be categorized in lymph node staging for colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 414.	1.1	7

#	ARTICLE	IF	CITATIONS
289	Prognostic effect of high pretreatment neutrophil to lymphocyte ratio on survival of patients with gastric adenocarcinoma in China. <i>International Journal of Biological Markers</i> , 2015, 30, 96-103.	0.7	7
290	Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. <i>Cancer Science</i> , 2017, 108, 2045-2051.	1.7	7
291	Enzymatically synthesized poly(amino-co-ester) polyplexes for systemic delivery of pcDNA-miRNA-214 to suppress colorectal cancer liver metastasis. <i>Journal of Materials Chemistry B</i> , 2018, 6, 6365-6376.	2.9	7
292	Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. <i>Cancer Communications</i> , 2020, 40, 620-632.	3.7	7
293	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 128-128.	0.8	7
294	Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15083-e15083.	0.8	7
295	Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 423-425.	0.7	7
296	Impact of body mass index on survival of esophageal squamous carcinoma patients in southern China. <i>Journal of Thoracic Disease</i> , 2015, 7, 337-45.	0.6	7
297	Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. <i>American Journal of Cancer Research</i> , 2020, 10, 2946-2954.	1.4	7
298	Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients. <i>Medical Oncology</i> , 2011, 28, 476-482.	1.2	6
299	Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. <i>OncoTargets and Therapy</i> , 2014, 7, 501.	1.0	6
300	POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. <i>Clinical and Translational Medicine</i> , 2021, 11, e524.	1.7	6
301	A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4025-4025.	0.8	6
302	Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 563407.	1.3	5
303	The drug treatment research of gastrointestinal cancer in China. <i>European Journal of Surgical Oncology</i> , 2020, 46, e3-e6.	0.5	5
304	Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 490-499.	0.7	5
305	Primary tumor immune score fails to predict the prognosis of colorectal cancer liver metastases after hepatectomy in Chinese populations. <i>Annals of Translational Medicine</i> , 2021, 9, 310-310.	0.7	5
306	A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. <i>Cancer Medicine</i> , 2021, 10, 1535-1544.	1.3	5

#	ARTICLE	IF	CITATIONS
307	Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform. <i>Engineering</i> , 2021, 7, 526-533.	3.2	5
308	Subgroup analysis by prior anti-VEGF for anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial. <i>Future Oncology</i> , 2021, 17, 1339-1350.	1.1	5
309	Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS365-TPS365.	0.8	5
310	Emerging immunological strategies: recent advances and future directions. <i>Frontiers of Medicine</i> , 2021, 15, 805-828.	1.5	5
311	Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting. <i>Journal of Cancer</i> , 2019, 10, 388-396.	1.2	4
312	A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients. <i>Cancer Management and Research</i> , 2019, Volume 11, 3993-4003.	0.9	4
313	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1). <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4150-TPS4150.	0.8	4
314	Effects of preoperative oral carbohydrate administration combined with postoperative early oral intake in elderly patients undergoing hepatectomy with acute-phase inflammation and subjective symptom burden: A prospective randomized controlled study. <i>Asian Journal of Surgery</i> , 2022, 45, 386-395.	0.2	4
315	A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3548-3548.	0.8	4
316	A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO). <i>Journal of Clinical Oncology</i> , 2017, 35, 3508-3508.	0.8	4
317	A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT). <i>Journal of Clinical Oncology</i> , 2017, 35, 681-681.	0.8	4
318	The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4735-4743.	0.5	4
319	Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 264.	1.4	3
320	Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 69-79.	1.1	3
321	Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study. <i>The Lancet Regional Health - Western Pacific</i> , 2020, 4, 100054.	1.3	3
322	Evaluation of <i>POLE</i> Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. <i>JAMA Oncology</i> , 2020, 6, 590.	3.4	3
323	The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy. <i>Medicine (United States)</i> , 2016, 95, e3214.	0.4	2
324	Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 8.	4.9	2

#	ARTICLE	IF	CITATIONS
325	Systematic analysis of the transcriptome in smallâ€cell carcinoma of the oesophagus reveals its immune microenvironment. <i>Clinical and Translational Immunology</i> , 2020, 9, e1173.	1.7	2
326	Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 98.	0.8	2
327	ASO Author Reflections: Radiopathomics Strategy of Combing Multi-scale Tumor Information on Pretreatment to Predict the Pathologic Response to Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 4307-4308.	0.7	2
328	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in theâ€FRESCO trial. <i>Future Oncology</i> , 2021, 17, 1923-1931.	1.1	2
329	Healing time of incision infection after hepatobiliary surgery treated by needle-free incision suture closure. <i>World Journal of Gastroenterology</i> , 2014, 20, 15815.	1.4	2
330	The Chinese Journal of Cancer is indexed in Science Citation Index (SCI) expanded. <i>Chinese Journal of Cancer</i> , 2014, 33, 367-8.	4.9	2
331	Retroperitoneal laparoscopic management method of Castleman's disease in the adrenal gland: two cases report and review of the literature. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 5909-12.	1.3	2
332	Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3106-3106.	0.8	2
333	A New Role for PHD in Chemotherapy. <i>Cancer Cell</i> , 2012, 22, 143-144.	7.7	1
334	p.P476S mutation of RBPJL inhibits the efficacy of antiâ€PDâ€1 therapy in oesophageal squamous cell carcinoma by blunting Tâ€cell responses. <i>Clinical and Translational Immunology</i> , 2020, 9, e1172.	1.7	1
335	The Role of Maintenance Therapy in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 937.	3.4	1
336	Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16022-e16022.	0.8	1
337	Performance of common genetic variants in risk prediction for colorectal cancer in Chinese: A two-stage and multicenter study. <i>Genomics</i> , 2021, 113, 867-873.	1.3	1
338	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4439-4450.	1.0	1
339	The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis. <i>Biomolecules</i> , 2021, 11, 1268.	1.8	1
340	The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4109-4109.	0.8	1
341	MET amplification occurrence and prediction of unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15047-e15047.	0.8	1
342	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3544-3544.	0.8	1

#	ARTICLE	IF	CITATIONS
343	Clinical response and biomarker analysis of POLARIS-02 a phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2020, 38, 6542-6542.	0.8	1
344	Identification of "regulation of RhoA activity panel" as a prognostic and predictive biomarker for gastric cancer. Aging, 2021, 13, 714-734.	1.4	1
345	Neoadjuvant chemoradiotherapy with or without Pd-1 antibody sintilimab for pMMR/MSS/MSI-L locally advanced rectal cancer: A randomized controlled study (cohort B).. Journal of Clinical Oncology, 2022, 40, TPS210-TPS210.	0.8	1
346	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. Journal of Clinical Oncology, 2022, 40, TPS370-TPS370.	0.8	1
347	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2022, 28, 3686-3694.	3.2	1
348	Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2022, 40, 11513-11513.	0.8	1
349	Circulating tumor DNA and recurrence risk in stage II-III gastric cancer.. Journal of Clinical Oncology, 2022, 40, 4054-4054.	0.8	1
350	Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer: Experiences of 16 patients in single institute. Chinese-German Journal of Clinical Oncology, 2009, 8, 669-674.	0.1	0
351	IDDF2019-ABS-0245"Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. , 2019, , .		0
352	Artificial intelligence applications in upper gastrointestinal cancers " Authors' reply. Lancet Oncology, The, 2020, 21, e5.	5.1	0
353	Relationship between prediagnostic body mass index trajectory and colorectal adenomas: an analysis of the PLCO cancer screening trial. Annals of Translational Medicine, 2020, 8, 815-815.	0.7	0
354	Correction: Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. Oncotarget, 2021, , .	0.8	0
355	Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Annals of Translational Medicine, 2021, 9, 893-893.	0.7	0
356	The Impact of Glucocorticoids for Cirrhosis Patients Performed Major Liver Resection: A Retrospective Control Study. Hepato-Gastroenterology, 2012, 59, 1220-4.	0.5	0
357	Evaluation of serum HER2 extracellular domain in in metastatic gastric or gastroesophageal junction cancer: Correlation with HER2 status by immunohistochemistry and fluorescence in situ hybridization and clinicopathologic parameters.. Journal of Clinical Oncology, 2013, 31, 4107-4107.	0.8	0
358	The relationship between HER2 expression and Lauren classification in Chinese gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 4065-4065.	0.8	0
359	Association between lymph node examination and nodal staging for pancreatic adenocarcinoma: A population-based analysis.. Journal of Clinical Oncology, 2017, 35, e15772-e15772.	0.8	0
360	Incidence rate and clinical-pathological features of hereditary diffuse gastric cancer patients in China.. Journal of Clinical Oncology, 2017, 35, 4065-4065.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Incidence rate and clinic-pathologic features of EBV-associated gastric carcinoma in China.. Journal of Clinical Oncology, 2018, 36, e16048-e16048.	0.8	0
362	Effect of knockdown of eukaryotic initiation factor 4A2 (eIF4A2) on growth, metastasis, and oxaliplatin sensitivity in colorectal cancer.. Journal of Clinical Oncology, 2018, 36, e15658-e15658.	0.8	0
363	Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.. Journal of Clinical Oncology, 2018, 36, 4045-4045.	0.8	0
364	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapelRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. Journal of Clinical Oncology, 2019, 37, 711-711.	0.8	0
365	Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside in prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer patients.. Journal of Clinical Oncology, 2019, 37, 674-674.	0.8	0
366	Study on Big Data-Supported Clinical Oncology. , 2020, , 325-349.		0
367	Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. American Journal of Cancer Research, 2020, 10, 3037-3046.	1.4	0
368	PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. American Journal of Cancer Research, 2021, 11, 5006-5015.	1.4	0
369	A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2022, 40, e15543-e15543.	0.8	0
370	Mutational profiles of sporadic synchronous colorectal cancer.. Journal of Clinical Oncology, 2022, 40, e15555-e15555.	0.8	0